RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health, investing in public and private companies across stages from seed to late-stage financings. The firm emphasizes evidence-based, science-led investing guided by internal research capabilities, including TechAtlas. It operates Raven, a biomedical innovation incubator that supports entrepreneurs and developers, and pursues value creation through collaborative partnerships, often co-investing and taking board positions. With a multidisciplinary, data-driven approach, RA Capital seeks to back management teams from inception through commercialization and beyond, aiming to improve patient outcomes and advance medical innovation.

OrbiMed is a global healthcare-focused investment firm founded in 1989 and headquartered in New York. It manages assets across public and private markets and pursues opportunities across the healthcare spectrum, including biopharmaceuticals, medical devices, diagnostics, digital health, and health services. The firm invests in startups, growth-stage companies, and established entities, leveraging scientific and medical expertise to support development and commercialization. It also offers financing solutions such as structured debt and royalty monetization for intellectual property and medical diagnostics.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm manages approximately $5.8 billion in assets under management and has invested in over 290 public and private healthcare companies worldwide. Its multi‑fund platform covers growth equity, private equity including buyouts, venture capital, and public equity, and it makes investments across biotechnology, pharmaceuticals, medical devices, and healthcare services in major markets, with a focus on the United States and China. The team comprises about 50 professionals including physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build and grow high‑quality healthcare companies.

Samsara BioCapital is a Palo Alto-based venture capital firm focused on biotechnology and transformative therapeutics. Founded in 2016, it invests in the healthcare sector across the United States and operates as an investment adviser. The firm collaborates with scientists, physicians, drug developers, and business leaders to support ambitious biotechnology companies and advance a portfolio of therapeutic projects aimed at delivering innovative medicines to patients.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven investments in life sciences, biotechnology, medical technologies, and related fields. The firm backs companies at multiple stages, often co-founded with scientists and entrepreneurs, aiming to translate academic research and national laboratory innovations into therapies, diagnostics, and other breakthrough technologies. ARCH emphasizes deep involvement, technical expertise, and a wide network to support founders from early development through later rounds, acting as a partner rather than a passive investor. With a focus on markets centered in the United States and North America, the firm frequently funds startups emerging from universities and research institutions and has built a track record of helping scientists bring innovations to market.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across multiple stages, from seed to growth and IPO, and provides strategic support in product development and market expansion. The firm targets sectors including software, AI, consumer technology, digital health, life sciences, and energy technology, and pursues opportunities worldwide. NEA emphasizes long-term partnerships with founders, drawing on domain expertise and a broad network to help portfolio companies scale. It maintains a diverse portfolio across the United States, Asia and other regions, reflecting a global approach to venture investing.

European Innovation Council is a European Union initiative established in 2018 to support deep-technology innovation and help startups, researchers, and small companies scale. It offers funding opportunities and business acceleration services, and engages in co-investment with private investors in early-stage ventures with ESG impact. The EIC emphasizes female entrepreneurship through programs such as Women TechEU and related awards, and provides resources to promote knowledge sharing and community building. Based in Brussels, it pursues a European-wide mandate to strengthen Europe's position in the global deep-tech ecosystem.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco. It invests across the healthcare sector, including life sciences, biotechnology, pharmaceuticals, and medical devices, at all stages with an emphasis on discovery and development of novel therapeutics. The firm operates globally with offices in Canada, the United States, and Europe, delivering hands-on support to portfolio companies through in-house scientific and operating expertise. Versant pursues collaborative partnerships with entrepreneurs to translate research into clinical and commercial success and has a track record of portfolio companies achieving successful acquisitions or IPOs. The firm is registered as an investment adviser.

Forbion is a venture capital firm based in Naarden, Netherlands, with over twenty years of experience investing in biotech and life sciences. It focuses on human health, planetary health, and the bioeconomy, supporting early-stage and growth investments across Europe and North America in drug development, MedTech, and sustainable solutions. Its portfolio includes gene therapy and other innovative therapies for rare diseases. Forbion manages funds totaling about €5 billion in committed capital across multiple vehicles and prioritizes ESG principles in its investment approach, seeking to accelerate scientific advances and drive long-term value for portfolio companies.

Deep Track Capital is a biotechnology investment firm based in Greenwich, Connecticut. It focuses on the life sciences and biotech sector, forging partnerships with management teams of innovative public and pre-IPO biotechnology companies, and aims to invest time, expertise, and its network alongside capital to support partners. The firm seeks to lead transactions while forming large syndicates and to participate in rounds led by other qualified investors.

Logos Capital is a San Francisco-based biotechnology investment firm founded in 2019 that combines in-house data analytics with scientific and clinical expertise to identify transformative therapies. The firm uses a disciplined, data-driven approach and a proprietary Logos Analytics platform to model clinical data, assess likelihood of clinical success, and support comprehensive underwriting, ongoing event tracking, and proactive risk management. Its team spans medical, scientific, and business disciplines, with the aim of delivering long-term returns through investments in therapies that have the potential to improve patient outcomes and redefine standards of care.

Deerfield Management is a New York City-based healthcare investment and information platform that advances healthcare through flexible funding models, AI-driven intelligence, and philanthropy. It connects people, capital, ideas, and technology across the healthcare ecosystem by investing in and building companies, powered by Deerfield Discovery and Development (3DC), a company-building R&D engine where bench scientists and industry veterans collaborate, and Cure, a New York City hub housing portfolio companies and in-building labs with advanced equipment. It has partnered with Blue Cross Blue Shield of North Carolina to build Alo, a platform enabling independent physicians to manage the business of medicine. Its Intelligence offering leverages AI, data, and market research to drive healthcare technology and innovation, while the Deerfield Foundation funds philanthropic initiatives in education, healthcare access, and health outcomes. The firm pursues strategic partnerships and external collaborations to accelerate progress across biotechnology, pharmaceuticals, diagnostics, devices, and services.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

TCG Crossover is a science-driven healthcare investment firm focused on identifying and advancing disruptive medicines. The firm invests in private and public biotechnology and health-technology companies led by entrepreneurs pursuing innovative treatments, with investment teams based in Palo Alto and New York City. Its approach emphasizes supporting ventures that aim to improve patient outcomes and accelerate pharmaceutical development through a research-driven portfolio and strategic backing.

Sofinnova Partners is an independent venture capital firm based in Paris, France, specializing in life sciences investments from seed to later stages. It backs start-ups, early-stage companies, corporate spin-offs, and occasionally turnarounds, with a focus on biopharmaceuticals, biotechnology, medical devices, industrial biotechnology and related healthcare sectors. The firm typically takes a lead or cornerstone investor role, often chairs or sits on boards, and supports portfolio companies from formation through growth toward exit. Founded in 1972, it has a long track record in partnering with entrepreneurs and managing substantial assets dedicated to life sciences investing.

SOSV is a global venture capital firm that provides early-stage and seed investments alongside structured accelerator programs and deeply resourced facilities to accelerate product development. Focused on deep tech, human and planetary health, and cross-border software, SOSV backs startups from pre-seed onward and runs programs that accelerate technical development, regulatory strategy, and fundraising. The firm maintains labs and engineering spaces with specialist staff in multiple regions, including the United States and Asia, to support portfolio companies in biosafety, chemistry, mechatronics, analytics, and electrical engineering. Programs such as HAX and other live events offer founders access to prototyping, testing, and investor networks. Annually, SOSV makes around sixty pre-seed investments (up to roughly $550k each) and participates in numerous follow-on rounds, leveraging a global portfolio and extensive co-investor network to help deeply technical startups scale and reach markets.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in building and funding early-stage biotechnology and life sciences companies, as well as technology ventures. Founded in 1980, it uses a seed-led venture creation approach to translate scientific discoveries into scalable medicines and biotech businesses, often acting as a lead investor and seeking board representation for portfolio companies.

Omega Funds is a Boston, Massachusetts-based venture capital firm focused on life sciences and healthcare investments across North America and Western Europe. The firm targets opportunities in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, leveraging an experienced team and broad network to support entrepreneurs and founders. It has facilitated the development of products reaching patients and has a track record that includes a public listing and an M&A deal. The firm operates across multiple funds and engages with the European ecosystem, sharing insights through publications such as the Omega Insights Series.

Boxer Capital is the corporate venture capital arm of Tavistock Group that concentrates its investments in biotechnology and life sciences. Based in San Diego, California, the firm pursues opportunities in both private and public biotechnology companies across the entire drug development lifecycle, from early discovery assets to late-stage clinical and commercial programs. It combines scientific expertise with investment experience to evaluate targets across therapeutic areas, emphasizes precision medicine, and seeks to support transformative medical advances through disciplined, research-driven analysis and active partnerships with portfolio companies.

SR One is the corporate venture capital arm of GlaxoSmithKline, a trans-Atlantic biotechnology investor focused on funding innovative science to develop new medicines. It operates from biotechnology hubs on the West Coast and in London, leveraging its cross-Atlantic presence to provide strategic partnerships, geographic reach, and portfolio support that accelerates the translation of scientific breakthroughs into medicines. Founded in 1985, SR One has invested about 800 million dollars in more than 180 life science companies, and it employs a back-and-build approach that prioritizes strong scientific fundamentals, clear development plans, and novel approaches to disease treatment.

EcoR1 Capital is a biotechnology-focused venture capital firm based in San Francisco. The firm seeks to invest in biotech companies and drug discovery programs, aiming to support scientific breakthroughs and develop new medicines. It pursues long-term partnerships with ambitious entrepreneurs and favors a collaborative approach that leverages curiosity and a deep understanding of molecular mechanisms to identify and realize opportunities in biology and chemistry. As a registered investment adviser, EcoR1 Capital positions itself to back innovative therapies addressing unmet medical needs and to contribute to advances that improve patients' lives.

HBM Healthcare Investments is a Swiss investment company that concentrates on the global healthcare sector, seeking to capitalize on innovation across private and public healthcare companies. Founded in 2001 and based in Switzerland, it maintains a diversified portfolio spanning human medicine, biotechnology, medical technology and diagnostics, with investments across private companies, public equities, and funds. The firm emphasizes high-value creation potential through its portfolio and positions itself to benefit from demographic trends, medical advancements and rising demand for new therapies.

Mission BioCapital is a life science venture capital firm focused on early-stage investments in biotechnology and related life sciences in the United States, with offices in Cambridge, Massachusetts and San Francisco. The leadership team has a long history of launching dozens of early-stage life science companies and a track record of providing deep expertise and support to portfolio companies. The firm emphasizes mentorship, collaboration, and founder-centric value creation, and offers programs such as the Platinum Program, which provides up to $500,000 in funding along with lab space and services including drug discovery, legal and financial assistance to accelerate development.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across Europe. It manages multiple funds, including early-stage life sciences funds, to support therapeutic and medical innovations from early concept to development, with active collaboration with academic research institutes and hospitals. The firm emphasizes a collaborative, hands-on approach, providing capital and strategic guidance to portfolio companies, often forming strong partnerships with research teams to translate scientific discoveries into medicines and medical devices. Kurma Partners targets investments in life sciences, pharmaceuticals, biotechnology, digital health and related technology sectors, and pursues opportunities across Europe, integrating ESG practices into its investment processes.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

MPM Capital is a Cambridge-headquartered healthcare investment firm that funds biotechnology, oncology, and life sciences companies. It invests across the company lifecycle, from seed and early development to growth and late-stage programs, aiming to translate scientific advances into clinical outcomes. The firm backs ventures in medical technology, oncology, specialty pharma, and medical devices and pursues global opportunities in the United States, Europe, and Asia, with a focus on India. Founded in 1996, MPM Capital collaborates with researchers, clinicians, and entrepreneurs to support portfolio companies through development milestones and proof-of-concept data.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. It focuses on seed- and early-stage investments in life sciences and healthcare, including biopharmaceuticals, biotechnology, drug delivery, medical technology, and research instruments, with additional interest in digital health and health technology. The firm maintains a Boston office and targets opportunities across the United States and North America, partnering with academics and entrepreneurs to build next-generation life science companies. It also operates an internal initiative called 4:59 to identify, incubate, and fund breakthrough science.

Casdin Capital is a New York-based investment firm focused on the life sciences and healthcare sectors. It targets biotechnology, genomics, precision medicine, oncology, digital health, and related technologies, applying data-driven, research-intensive analysis to identify disruptive opportunities in the field. The firm makes private investments across stages and seeks to partner with companies developing innovative therapies, diagnostics, and tools that advance healthcare. Founded in 2012 by Eli Casdin, Casdin Capital operates as a registered investment adviser and emphasizes a long-term, fundamental approach to identifying paradigm shifts in life sciences.

VenBio Partners is a California-based venture capital firm with offices in San Francisco and Seattle, focused on life sciences and investing across the development spectrum in the United States. The firm aims to lead most of its investments and actively builds syndicates and teams to support portfolio companies. It emphasizes positions that enable potential acquisition partners, prioritizing strong intellectual property, CMC capabilities, and clearly defined clinical development plans, including trial design, endpoints, powering, and regulatory considerations. VenBio provides strategic guidance throughout development to maximize impact and foster long-term relationships with leaders in the field.

Commodore Capital is a New York-based venture capital firm founded in 2019 that concentrates on the biopharmaceutical sector. It focuses on early-stage opportunities within smaller biopharmaceutical companies, partnering to advance innovative modalities such as genetic medicines and cellular therapies. The firm aims to translate scientific discoveries into clinical breakthroughs that improve patients' lives by backing companies developing safe and effective medicines for patients worldwide.

Merck is a global pharmaceutical company focused on discovering, developing, and delivering medicines and vaccines to treat cancer, infectious diseases, and other conditions. It emphasizes oncology through its immuno-oncology platform, with Keytruda as a major product contributor, and maintains a substantial vaccine business that includes Gardasil to prevent human papillomavirus infections. The company also targets cardiometabolic, infectious, immunology, neuroscience, and ophthalmology areas, supported by a robust pipeline and clinical development efforts powered by data science and AI. Merck pursues responsible operations, sustainability initiatives, and patient access programs, while maintaining transparency with stakeholders. Its activities span global markets, with emphasis on innovative partnerships to expand healthcare impact and address unmet medical needs.

Takeda Pharmaceutical is a global biopharmaceutical leader and Japan’s largest pharmaceutical company. It researches, develops, manufactures, and markets prescription medicines and vaccines across oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The company serves patients worldwide with a diversified geographic footprint—roughly half of revenue from the United States, about 10% from Japan, 25% from Europe, and 15% from Canada. Takeda emphasizes patient-centered growth, sustainability, and ethical practices, supported by a strong focus on research and development to translate science into transformative medicines.

Ally Bridge Group is a private investment firm focused on healthcare and life sciences, with offices in New York and Hong Kong. Founded in 2013, it pursues venture, growth, private equity, and public equity investments across private and public markets in the United States, China, and Europe, targeting innovative drugs, medical devices, diagnostics, and digital health platforms. The firm combines scientific and clinical insight with capital markets expertise to bridge healthcare innovations with global markets, aiming to generate superior risk-adjusted returns while supporting portfolio companies through development and scale.

Aisling Capital is a New York-based investment firm focused on healthcare and life sciences. Founded in 2000, it specializes in biopharmaceutical development and commercialization, investing in companies across the United States, Western Europe, and Canada. The firm supports mid- to late-stage ventures and growth companies seeking to advance therapies from discovery to commercialization, drawing on extensive healthcare industry experience. With more than $1.8 billion in assets and a track record across genomics-defined cancers, neuroscience and other central nervous system disorders, Aisling Capital aims to back global healthcare innovators and translate scientific breakthroughs into approved products.

Abingworth is an international life sciences investment firm founded in 1973 with offices in London, Menlo Park, and Boston. It invests across the development spectrum—from seed-stage to publicly traded companies—and across sectors including healthcare, biotechnology, pharmaceuticals, and medical devices in the United States and Europe. The firm collaborates with life sciences entrepreneurs to translate scientific advances into health-impacting products, providing capital and strategic guidance through its portfolio companies. With over $1 billion under management and a dedicated team, Abingworth has backed more than 140 life science companies and supported many IPOs and strategic transactions, reflecting a focus on advancing therapeutics and related technologies.

Pivotal bioVenture Partners is a San Francisco–based venture capital firm that specializes in life sciences and therapeutic devices. Founded in 2016, the firm funds privately held biotechnology, therapeutics, medical devices, diagnostics, and related services companies across North America, Europe, and Greater China. It invests across the company lifecycle, from creation through mid- and late-stage clinical development, and supports founders with a team that combines venture experience with drug discovery and development expertise. The firm operates through regional vehicles, including Pivotal BioVenture Partners China in Shanghai and other U.S. and European-focused funds, and manages more than three billion dollars in assets. Its strategy emphasizes advancing innovative products to address unmet medical needs and building new ventures that accelerate healthcare breakthroughs.

Third Rock Ventures is a Boston-based venture capital firm focused on early-stage life sciences and healthcare companies. Founded in 2007, it targets companies developing therapies, diagnostics, devices, and related technologies that address unmet medical needs. The firm seeks meaningful, high-growth opportunities in the United States, often leading initial investments and engaging actively in portfolio companies, sometimes taking management roles or forming strategic collaborations with larger pharmaceutical and biotechnology partners. Third Rock emphasizes hands-on involvement and strategic support to accelerate product development and market progress, with a history of funding companies across oncology, cardiovascular, immunology, gene therapy, and other therapeutic areas. The firm operates through multiple venture funds and maintains a focus on Boston, with additional presence in San Francisco, and aims to foster patient-centric, transformative medicines and technologies.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, including oncology and drug discovery. It supports startups from early discovery through commercialization, taking a long-term view to build companies around robust scientific platforms and multiple product opportunities rather than short-term exits. The firm emphasizes deep scientific expertise, strong teams, collaboration, and mentorship, exemplified by the Swanson Fellowship. It manages more than $4 billion in assets and has backed about 55 biotech companies, generating substantial returns and multiple exits. The organization operates a portfolio of funds to support its activities from discovery to market and maintains an edge-to-edge, long-term investment approach.

Longitude Capital is a venture growth investment firm focused on biotechnology, medical technology, and health solutions. The firm targets both privately held and publicly traded life sciences companies and builds a diversified portfolio of clinically de-risked assets at clinical- or commercial-stage horizons. It utilizes a range of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties and other equity-linked instruments, and it often leads or co-leads portfolio investments. Founded in 2006 and based in Menlo Park, California, with an office in Boston, the firm leverages an extensive industry network and proprietary research to identify opportunities. Longitude Capital has raised substantial capital across multiple funds and has a history of sourcing, managing and exiting investments, including acquisitions by major pharmaceutical companies.

New Leaf Venture Partners is a New York-based venture capital firm focused on healthcare technology investments. It backs later-stage biopharmaceutical products, early-stage medical devices, laboratory infrastructure technologies, and related life sciences tools and information convergence. The team traces its origins to Sprout Group, the venture capital affiliate of Credit Suisse First Boston, with healthcare technology investing beginning in 1993 and a 2005 spin-out to form New Leaf Venture Partners. The firm seeks opportunities to partner with companies poised for meaningful growth and impact in healthcare, providing strategic funding and guidance to accelerate innovation and improve patient outcomes.

IMM Investment is a Seoul-based asset manager and private equity firm specializing in venture capital, growth equity, infrastructure, mezzanine and multi-asset strategies. Founded in 1999, it operates across Asia with offices in Seoul, Tokyo and Hong Kong, and pursues investments in information technology, healthcare/biotech and manufacturing, as well as technology-enabled sectors such as IT infrastructure and digital hardware. The firm emphasizes active ownership, collaboration with portfolio companies, and cross-border opportunities, including fund-of-funds and real estate. It targets mid-sized companies in South Korea and broader Asia, focusing on value creation through growth, mergers and acquisitions, and strategic recapitalizations, and manages a multi-stage investment approach across startups, expansion and mezzanine rounds. The team, comprising seasoned investment professionals, aims to deliver strong risk-adjusted returns and supports entrepreneurs through various growth phases.

Pontifax Venture Capital is a Herzliya, Israel-based venture capital firm that specializes in healthcare and life sciences. The firm invests across the development spectrum, from early-stage startups to growth-stage clinical companies, with a focus on pharmaceutical, biotechnology, medical devices, diagnostics, and related healthcare technologies. It seeks disruptive ideas typically sourced from research centers and provides active, hands-on support, including strategic guidance, networking, and experience in M&A to help portfolio companies scale. While headquartered in Israel, Pontifax invests globally and maintains a presence that reflects broad access to innovation in life sciences. Since its founding in 2004, Pontifax has built a diversified portfolio of companies across life sciences and healthcare technology.

Seventure Partners is a Paris-based venture capital firm that acts as an active partner to innovative companies at the intersection of digital technologies and life sciences. Founded in 1997, it helps entrepreneurs translate scientific and digital breakthroughs into global businesses. The firm focuses on two main verticals: Life Sciences (biotech, healthcare, nutrition, animal health, and industrial biotech) and Digital Technologies (fintech, retailtech, cybersecurity, hardware, telecom, sports and well-being). It also backs blue economy and sustainability initiatives, including aquaculture, biopolymers and biopackaging, climate and carbon solutions, recycling, and bioenergies. With a team of experienced investors, Seventure provides strategic guidance, networks, and resources to accelerate growth for ambitious teams across Europe, North America, and beyond. The firm is based in Paris and maintains relationships with institutional partners to support its portfolio.

Lumira Ventures is a North American life sciences venture capital firm with offices in Toronto, Montreal, Vancouver and Boston. Founded in 1989, it partners with entrepreneurial management teams to build biotherapeutic, medical device, digital health and consumer health companies that address unmet needs and drive transformation. The firm focuses on biotechnology, biopharmaceuticals, medical devices, digital health and related sectors in Canada and the United States. It typically makes multi-million dollar investments and participates actively on boards to accelerate technology development, access follow-on funding, and foster strategic partnerships. Lumira Ventures has invested in more than 100 healthcare companies and maintains a portfolio of over 30 active investees across North America.

Andreessen Horowitz is a Menlo Park, California-based venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz. It funds technology startups across seed to late stages, with investments spanning software, cloud infrastructure, enterprise software and services, consumer internet, fintech, artificial intelligence, crypto, infrastructure, and biotechnology at the intersection of computer science and life sciences. The firm emphasizes supporting portfolio companies through growth and strategic partnerships and maintains a broad tech-focused investment approach, aiming to add value beyond capital.

Decheng Capital is a global venture capital and private equity firm founded in 2012 that concentrates on life sciences and healthcare. It provides capital and strategic support to early-stage life science companies and growth-stage healthcare businesses, seeking opportunities in life science tools, biopharmaceuticals, medical devices, diagnostics, digital health, and agricultural biotechnology. Headquartered in Menlo Park, California, with offices in Shanghai and New York, the firm emphasizes leveraging experienced professionals and relationships with prestigious limited partners to build globally oriented companies. Its portfolio activity includes investments in gene editing and cell therapies, reflecting a focus on breakthrough technologies and therapies that address significant medical needs.

Lux Capital is a venture capital firm focused on investing in companies at the intersection of science, technology, and industry. The firm backs ventures applying research across sectors including artificial intelligence, biotechnology, advanced materials, space, and energy, with an emphasis on translating complex innovations into scalable businesses. Lux provides capital together with strategic input on product development, company building, and long-term positioning, and takes an active role to help founders navigate technical and market challenges. The firm evaluates opportunities based on the underlying science, potential industry impact, and feasibility of execution over extended horizons. With offices in New York and Silicon Valley, Lux collaborates with technical founders, researchers, and teams to build durable market leaders and accelerate scientific breakthroughs into real-world applications.

Hatteras Venture Partners is a North Carolina–based venture capital firm that invests in biotech, Medtech, diagnostics, healthtech, and related human medicine opportunities in the United States. It collaborates with founders to prioritize high‑quality science and teams with meaningful patient impact, providing extensive support beyond capital, including team recruitment, portfolio strategy, and regulatory planning. With a track record spanning more than 25 years and more than 100 companies built, Hatteras maintains a national investment footprint and a broad network of industry partners to create optionality and drive early‑stage growth while managing calculated risk. Founded in 2000, the firm focuses on early‑stage to growth opportunities across biopharmaceuticals, medical devices, diagnostics, and healthcare IT in the life sciences and healthcare sectors.

Data Collective, also known as DCVC, is a San Francisco-headquartered venture capital firm that backs technology startups across the United States, with a focus on deep tech and early-stage investments. The firm supports companies applying advances in science and engineering to real-world problems, emphasizing teams that leverage compute and algorithmic advantages to reduce capital expenditures and operating costs. By funding entrepreneurs from seed to Series B, DCVC aims to advance disruptive technologies and scalable business models that benefit broader society.